Abstract: The embodiments of the present disclosure provide a display module and a middle frame, the display module includes a backlight module and a display panel, the backlight module includes a back plate, a first light source, a middle frame. The back plate includes a bottom plate, the first light source is on the bottom plate, the middle frame is between the bottom plate and the display panel. A side of the middle frame close to the display panel includes a first bearing portion and a second bearing portion, the first bearing portion is at an edge of the middle frame, a second light source is on the first bearing portion, the second bearing portion is on a side of the first bearing portion close to a display region of the display panel, the second bearing portion is connected to a position of the display panel corresponding to the display region.

Abstract: The present invention relates to the field of treatment of diseases. Specifically, the present invention relates to an anti-ROR1 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding same, and methods for preparing same. The anti-ROR1 antibody or the antigen-binding fragment thereof of the present invention has high specificity and high affinity for ROR1, and can effectively bind ROR1 and mediate killing of ROR1 expression cells. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in preparation of a drug which is used for prevention and/or treatment of tumors.

Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.

Abstract: The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.

Abstract: Growth factors are of great potential in regenerative medicine. However, their clinical applications are largely limited in by short in vivo half-lives and a narrow therapeutic window. Thus, a robust controlled release system remains an unmet medical need for growth-factor-based therapies. A nanoscale controlled release system (degradable protein nanocapsule) is provided via in-situ polymerization on growth factor. The release rate can be finely tuned by engineering the surface polymer composition. Improved therapeutic outcomes are achieved with the growth factor nanocapsules, as illustrated in spinal cord fusion mediated by bone morphogenetic protein-2 (BMP-2) nanocapsules.

Abstract: A manufacturing method for LTPS TFT substrate is disclosed. Through performing two etchings on the gate metal layer, ion heavy doping and ion light doping of the polysilicon active layer are performed in a self-aligned manner such that the LDD structure of the polysilicon active layer is symmetrically distributed on two sides of the gate electrode, which is beneficial to improve device characteristics, is more stable and reliable than the conventional technology, and can reduce the number of process masks, save mask cost, operation cost, material cost and the time cost. The thinning process of the gate insulation layer can reduce the thickness of the gate insulation layer corresponding to the heavily doped region of the polysilicon active layer, so that the ion implantation efficiency can be effectively improved.